Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

# Sapacitabine

## Catalog No: tcsc0006340

### Available Sizes

**Size:** 5mg

**Size:** 10mg

**Size:** 25mg

**Size:** 50mg

**Size:** 100mg

### Specifications

**CAS No:**
151823-14-2

**Formula:**
$C_{26}H_{42}N_4O_5$

**Pathway:**
Cell Cycle/DNA Damage

**Target:**
Nucleoside Antimetabolite/Analog

**Purity / Grade:**
>98%

**Solubility:**
DMSO : 25 mg/mL (50.95 mM; Need ultrasonic and warming)

**Alternative Names:**
CS682;CYC682

Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

**Observed Molecular Weight:**
490.64

## Product Description

Sapacitabine is an orally available **nucleoside analog** prodrug that is structurally related to cytarabine.

IC50 & Target: nucleoside analog[1]

***In Vitro:*** Concentrations of Sapacitabine required to achieve an $IC_{50}$ range from 3±0.6 μM for the colon cancer cell line HCT116 to 67±14 μM for the breast cancer cell line MDA-MB-435. Cell cycle analysis shows that 35% Sapacitabine-treated cells are arrested in late-S phase and 41% in $G_2$/M phase. L1210 cells with deoxycytidine kinase (dCK) activity are sensitive to Sapacitabine, ($IC_{50}$ 20±6 μM). In the docetaxel/Sapacitabine combinations, synergistic effects (CI[1].

***In Vivo:*** On Day 14, the Sapacitabine (5 mg/kg)+vorinostat (33 mg/kg) group has a mean tumour volume of 245 $mm^3$ and a tumour growth inhibition (TGI) of 92%, whereas the Sapacitabine (15 mg/kg)+vorinostat (33 mg/kg) group has a mean tumour volume of 107 $mm^3$ and a TGI of 112%[2].